Tesamorelin Dosage Guide: Starting Protocol and Titration

Tesamorelin is one of the few growth hormone releasing peptides with a real regulatory paper trail behind it, which is exactly why the dosing questions come up so often. People want to know how much to run, when to inject, how long to stay on, and where the number 2 mg actually comes from. This guide walks through the standard tesamorelin dosage, how research users titrate into it, timing, cycle length, and the side effects worth watching. None of this is medical advice, and tesamorelin sold through research vendors is labeled for laboratory use only.

What Tesamorelin Is and Why Dose Matters

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH). Instead of adding growth hormone directly, it prompts the pituitary to release your own GH in a more natural pulsing pattern. It is FDA approved under the brand name Egrifta, approved in 2010 for the reduction of excess visceral abdominal fat in people with HIV associated lipodystrophy. That approval is the source of almost every dosing figure you will see quoted, because the pivotal trials were built around a specific dose.

Dose matters here more than with some peptides because tesamorelin works by amplifying a hormonal signal. Too little and the GH pulse is not meaningfully changed. Too much does not linearly add benefit and instead raises the odds of fluid retention, joint discomfort, and shifts in blood sugar. Getting the dose right is most of the protocol.

The Standard Tesamorelin Dosage

The clinically studied and approved tesamorelin dose is 2 mg once daily, given as a subcutaneous injection. That is the figure carried through the Egrifta label and the phase 3 trials, where 2 mg daily reduced visceral adipose tissue by a meaningful margin over 26 weeks compared to placebo. If you only remember one number from this page, it is 2 mg per day.

Research users frequently start below the full dose to feel out tolerance. A common on-ramp looks like this:

The approved label does not require this titration, it uses a flat 2 mg from day one. The gradual approach is simply a way research users soften the early water retention and joint aches that some people report in the first two weeks. If you tolerate 2 mg cleanly, there is no evidence that pushing past it adds benefit, and higher doses mostly add side effects.

Reconstitution and Measuring Your Dose

Tesamorelin arrives as a lyophilized (freeze dried) powder that has to be reconstituted with bacteriostatic water before use. The concentration you mix determines how many units you draw, so this step is where dosing errors usually happen.

A clean setup for a 10 mg vial is 2 mL of bacteriostatic water, which gives you 5 mg/mL. At that concentration a 2 mg dose is 0.4 mL, which is 40 units on a standard U-100 insulin syringe. A 1 mg starting dose is 0.2 mL, or 20 units. If your vial is a different size, redo the math rather than assuming. Our full walkthrough on how to reconstitute peptides covers the mixing technique, and the reconstitution calculator handles the units for any vial and water combination.

Timing: When to Inject Tesamorelin

Tesamorelin is dosed once daily, and the most common timing choice is before bed on an empty stomach. There are two reasons for this. First, your largest natural GH pulse happens during early sleep, so an evening dose tends to ride with the body's own rhythm rather than against it. Second, elevated blood glucose blunts GH release, so keeping the injection away from meals, ideally with a couple of hours of fasting on either side, gives a cleaner pulse.

Some users prefer a morning fasted dose if their schedule makes nighttime injections inconvenient. Consistency matters more than the exact hour. Pick a window, keep food out of it, and inject at roughly the same time each day. The mechanics of the injection itself are the same as any subcutaneous peptide, and our peptide injection guide covers site rotation and technique.

Cycle Length: How Long to Run Tesamorelin

The trials that earned tesamorelin its approval ran continuously for 26 weeks, with an extension phase to 52 weeks. Visceral fat reduction generally became measurable around the 3 month mark, which tells you this is not a fast compound. It rewards patience.

Research users commonly plan cycles of 12 to 26 weeks and then reassess. One important detail from the clinical data: the visceral fat benefit tends to reverse once tesamorelin is discontinued, with fat gradually returning over the following months. That reversibility is why cycle planning and a maintenance strategy matter, rather than treating it as a one and done course. Some people run longer continuous protocols, others cycle off and rely on training and diet to hold gains between rounds.

What to expect on the timeline

• Weeks 1 to 2: Possible water retention, mild joint stiffness, occasional injection site redness. Sleep quality often improves.
• Weeks 3 to 8: Early side effects usually settle. Subtle changes in recovery and skin.
• Weeks 8 to 16: Visceral fat reduction becomes noticeable, waist measurements start moving.
• Beyond 16 weeks: Continued gradual visceral fat loss, plateau considerations, decision point on continuing or cycling off.

Stacking Tesamorelin

Because tesamorelin is a GHRH analog, it pairs logically with a ghrelin receptor agonist. The classic combination is tesamorelin with ipamorelin (a tested ipamorelin vial), since the two hit different receptors and together produce a larger, cleaner GH pulse than either alone. Ipamorelin is a favorite partner because it does not spike cortisol or prolactin at sensible doses.

A related family of stacks uses CJC-1295, which is itself a GHRH analog, so running it alongside tesamorelin is redundant rather than synergistic. If you want the GHRH plus ghrelin approach, tesamorelin plus ipamorelin makes more sense than doubling up on two GHRH compounds. Keep in mind that stacking amplifies the GH response, which also amplifies the water retention and blood sugar effects, so stacked protocols usually start conservative on both compounds.

People often compare tesamorelin to other growth hormone tools when planning a stack. It sits in the same conversation as MK-677, an oral secretagogue, and the older sermorelin protocols, though tesamorelin has the stronger clinical record for visceral fat specifically.

Side Effects to Watch at Dose

Tesamorelin is generally well tolerated at 2 mg, but the side effect profile is dose linked, which is another reason not to chase higher numbers. The most reported effects in trials and in practice are:

• Fluid retention: Puffiness in the hands or ankles, most common in the first two weeks. Usually settles, and titrating in helps.
• Joint aches and stiffness: A classic GH related effect. Mild and transient for most, worse at higher doses.
• Injection site reactions: Redness or itching. Rotating sites reduces this.
• Blood sugar shifts: Growth hormone is counter regulatory to insulin, so tesamorelin can nudge fasting glucose upward. This matters for anyone with insulin resistance and is worth monitoring.
• Carpal tunnel type symptoms: Tingling in the hands at higher doses, tied to fluid retention.

The blood sugar point is the one to take seriously. Tesamorelin was not shown to worsen long term glycemic control in the HIV trials, but it does raise GH, and GH opposes insulin. If glucose regulation is already a concern, this is a compound to approach carefully. For a broader look at what to expect across GH peptides, see our overview of peptide side effects.

Quality and Sourcing at This Dose

Dosing accuracy only means something if the vial actually contains what the label says. Tesamorelin is a longer, more fragile peptide than something like BPC-157, and underdosed or degraded product is a real problem in the research market. A vial that is half potency turns your carefully measured 2 mg into an effective 1 mg, and you would never know from the outside.

This is why we only point readers to vendors that publish batch specific certificates of analysis showing identity and purity by HPLC and mass spectrometry. The gap between a tested tesamorelin vial and an untested one is the difference between a protocol you can reason about and a guess. Our vendor scorecard tracks which suppliers actually post current COAs versus those that just claim purity.

Key Takeaways

• The standard studied tesamorelin dose is 2 mg once daily, subcutaneous.
• Many research users titrate in from 1 mg over one to two weeks to soften early side effects.
• Inject once daily, commonly before bed, on an empty stomach for a cleaner GH pulse.
• Visceral fat reduction shows up around the 3 month mark, so cycles of 12 to 26 weeks are typical.
• Benefits tend to reverse after stopping, so plan the cycle and a maintenance approach.
• Stacks pair tesamorelin (GHRH) with ipamorelin (ghrelin agonist), not with another GHRH like CJC-1295.
• Watch fluid retention, joint aches, and especially blood sugar at dose.
• Only source from vendors with current third-party COAs, since underdosing quietly wrecks your protocol.

Frequently Asked Questions

What is the standard tesamorelin dosage?

The clinically studied tesamorelin dose is 2 mg once daily by subcutaneous injection. That figure comes from the FDA approved product Egrifta, trialed at 2 mg daily for reducing excess visceral fat. Research users often start lower, around 1 mg daily, to gauge tolerance before moving to the full 2 mg.

When should tesamorelin be injected?

Tesamorelin is typically injected once daily, and many protocols place the dose before bed. Timing it at night lines the GH pulse up with the body's natural overnight release and keeps daytime food away from the injection window.

How long is a tesamorelin cycle?

Clinical trials ran tesamorelin continuously for 26 to 52 weeks, with visceral fat reduction appearing around the 3 month mark. Research users commonly run cycles of 12 to 26 weeks, then reassess. Benefits tend to reverse when the compound is stopped, so cycle planning matters.

Does tesamorelin need to be titrated?

The approved label uses a flat 2 mg daily dose with no formal titration. In practice many people ease in from 1 mg to 2 mg over one to two weeks to reduce the water retention and joint aches that can show up early.

Can tesamorelin be stacked with other peptides?

Tesamorelin is a GHRH analog, so stacking it with a ghrelin agonist like ipamorelin is a common approach to amplify the GH pulse. Because both push GH higher, side effects and blood sugar shifts can stack too, so this is done cautiously.

How is tesamorelin reconstituted?

Tesamorelin ships as a lyophilized powder, reconstituted with bacteriostatic water and stored refrigerated. A common setup is 2 mL of bacteriostatic water in a 10 mg vial, giving 5 mg/mL, so a 2 mg dose is 0.4 mL. Always confirm the math against your own vial size.